In-Depth Notes on Pharmacology of Endocrine Drugs

Oral Antidiabetic Drugs
Classifications

  • Antidiabetic drugs are categorized into various classes based on their mechanism of action, effects on insulin, and additional actions:

    1. Sulphonylureas

    2. Meglitinides

    3. Biguanides

    4. α-Glucosidase Inhibitors

    5. Thiazolidinediones

    6. Dipeptidyl Peptidase-4 (DPP-4) Inhibitors

    7. Glucagon-like Peptide-1 (GLP-1) Agonists

    8. Sodium-Glucose Cotransporter 2 (SGLT-2) Inhibitors

Mechanisms of Action and Indications

  1. Sulphonylureas:

    • Mechanism: Stimulate insulin secretion from pancreatic beta cells by closing potassium channels, leading to cell depolarization and calcium influx, which triggers insulin release.

    • Indications: Primarily used in type 2 diabetes. Examples include glyburide, glipizide, and glimepiride.

  2. Meglitinides:

    • Mechanism: Similar to sulphonylureas but with a quicker onset and shorter duration of action. They stimulate insulin release in response to meals.

    • Indications: Effective for patients with irregular meal times. Examples include repaglinide and nateglinide.

  3. Biguanides:

    • Mechanism: Improve insulin sensitivity in peripheral tissues, reduce gluconeogenesis in the liver, and slow glucose absorption from the intestine.

    • Indications: First-line therapy for type 2 diabetes, especially for overweight patients. Metformin is the most common biguanide.

  4. α-Glucosidase Inhibitors:

    • Mechanism: Inhibit the enzyme α-glucosidase in the intestines, delaying carbohydrate absorption and lowering postprandial glucose levels.

    • Indications: Often used in combination with other antidiabetic medications. Acarbose and miglitol are examples.

  5. Thiazolidinediones (TZDs):

    • Mechanism: Activate peroxisome proliferator-activated receptor gamma (PPAR-γ), leading to increased insulin sensitivity in adipose tissue, muscle, and the liver.

    • Indications: Used in type 2 diabetes, particularly for patients with insulin resistance. Pioglitazone and rosiglitazone are common TZDs.

  6. Dipeptidyl Peptidase-4 (DPP-4) Inhibitors:

    • Mechanism: Inhibit DPP-4 enzyme, thereby preventing the breakdown of incretin hormones, which increase insulin release and decrease glucagon levels.

    • Indications: Useful in type 2 diabetes management. Examples include sitagliptin, saxagliptin, and linagliptin.

  7. Glucagon-like Peptide-1 (GLP-1) Agonists:

    • Mechanism: Mimic the effects of GLP-1, enhancing insulin secretion in response to meals, suppressing glucagon secretion, and slowing gastric emptying.

    • Indications: Approved for type 2 diabetes, they help with weight loss. Examples include liraglutide and semaglutide.

  8. Sodium-Glucose Cotransporter 2 (SGLT-2) Inhibitors:

    • Mechanism: Inhibit SGLT-2 in the kidneys, leading to increased glucose excretion in urine and lowering blood glucose levels.

    • Indications: Help reduce the risk of cardiovascular events and renal issues in patients with type 2 diabetes. Examples include canagliflozin and dapagliflozin.

Adverse Effects

  • Vary by class; notable mentions include:

    • Hypoglycemia (especially with sulphonylureas and meglitinides)

    • Gastrointestinal disturbances (common with biguanides and α-glucosidase inhibitors)

    • Weight gain (often seen with TZDs)

    • Edema and heart failure risk (related to TZDs and some GLP-1 agonists)

These drugs should be combined with lifestyle changes, including diet and exercise, for optimal diabetes management, aiming to achieve and maintain glycemic control.

Classifications - Antidiabetic drugs are categorized into various classes based on their mechanism of action, effects on insulin, and additional actions:1. Sulphonylureas 2. Meglitinides 3. Biguanides 4. α-Glucosidase Inhibitors 5. Thiazolidinediones 6. Dipeptidyl Peptidase-4 (DPP-4) Inhibitors 7. Glucagon-like Peptide-1 (GLP-1) Agonists 8. Sodium-Glucose Cotransporter 2 (SGLT-2) Inhibitors ##### Mechanisms of Action and Indications 1. Sulphonylureas: - Mechanism: Stimulate insulin secretion from pancreatic beta cells by closing potassium channels, leading to cell depolarization and calcium influx, which triggers insulin release. - Indications: Primarily used in type 2 diabetes. Examples include glyburide, glipizide, and glimepiride. 2. Meglitinides: - Mechanism: Similar to sulphonylureas but with a quicker onset and shorter duration of action. They stimulate insulin release in response to meals. - Indications: Effective for patients with irregular meal times. Examples include repaglinide and nateglinide. 3. Biguanides: - Mechanism: Improve insulin sensitivity in peripheral tissues, reduce gluconeogenesis in the liver, and slow glucose absorption from the intestine. - Indications: First-line therapy for type 2 diabetes, especially for overweight patients. Metformin is the most common biguanide. 4. α-Glucosidase Inhibitors: - Mechanism: Inhibit the enzyme α-glucosidase in the intestines, delaying carbohydrate absorption and lowering postprandial glucose levels. - Indications: Often used in combination with other antidiabetic medications. Acarbose and miglitol are examples. 5. Thiazolidinediones (TZDs): - Mechanism: Activate peroxisome proliferator-activated receptor gamma (PPAR-γ), leading to increased insulin sensitivity in adipose tissue, muscle, and the liver. - Indications: Used in type 2 diabetes, particularly for patients with insulin resistance. Pioglitazone and rosiglitazone are common TZDs. 6. Dipeptidyl Peptidase-4 (DPP-4) Inhibitors: - Mechanism: Inhibit DPP-4 enzyme, thereby preventing the breakdown of incretin hormones, which increase insulin release and decrease glucagon levels. - Indications: Useful in type 2 diabetes management. Examples include sitagliptin, saxagliptin, and linagliptin. 7. Glucagon-like Peptide-1 (GLP-1) Agonists: - Mechanism: Mimic the effects of GLP-1, enhancing insulin secretion in response to meals, suppressing glucagon secretion, and slowing gastric emptying. - Indications: Approved for type 2 diabetes, they help with weight loss. Examples include liraglutide and semaglutide. 8. Sodium-Glucose Cotransporter 2 (SGLT-2) Inhibitors: - Mechanism: Inhibit SGLT-2 in the kidneys, leading to increased glucose excretion in urine and lowering blood glucose levels. - Indications: Help reduce the risk of cardiovascular events and renal issues in patients with type 2 diabetes. Examples include canagliflozin and dapagliflozin. ##### Adverse Effects - Vary by class; notable mentions include:- Hypoglycemia (especially with sulphonylureas and meglitinides) - Gastrointestinal disturbances (common with biguanides and α-glucosidase inhibitors) - Weight gain (often seen with TZDs) - Edema and heart failure risk (related to TZDs and some GLP-1 agonists) These drugs should be combined with lifestyle changes, including diet and exercise, for optimal diabetes management, aiming to achieve and maintain glycemic control.